Fecal Calprotectin in Pediatric Gastrointestinal Disorders
Observational · No treatment assigned · Sites not listed yet · Assiut University
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Gastrointestinal Diseases and Inflammatory Bowel Diseases. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 2 to 18
- Any sex
Some of the main requirements, copied from the record:
- \- Age 2 to 18 years
- Chronic gastrointestinal symptoms of more than 4 weeks duration (chronic diarrhea, recurrent abdominal pain, rectal bleeding, unexplained weight loss, or failure to thrive)
- Scheduled for upper gastrointestinal endoscopy and/or ileocolonoscopy with mucosal biopsy
Plus 1 more requirement(s). There are also 6 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 120 participants are expected to take part.
- Start date: 2026-09-02 (planned).
- Main results expected around 2027-09-02 (estimate from the record).
- No study sites are listed yet. Check the official record for contact details.
Main thing being measured
- Diagnostic performance of fecal calprotectin (Baseline)
In the researchers’ words
This prospective cross-sectional study aims to evaluate the diagnostic value of fecal calprotectin as a non-invasive biomarker in children with gastrointestinal disorders and to assess its correlation with endoscopic and histopathological findings at Assiut University Children Hospital.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Gastrointestinal Diseases; Inflammatory Bowel Diseases |
| Lead sponsor | Assiut University |
| Enrollment | 120 (estimated) |
| Start date | 2026-09-02 |
| Primary completion (est.) | 2027-09-02 |
| First posted | 2026-09-08 |
| Last updated | 2026-09-08 |
| Official title | Diagnostic Value of Fecal Calprotectin in Gastrointestinal Disorders Versus Its Correlation With Endoscopic and Histopathological Findings |
| ClinicalTrials.gov ID | NCT07807527 |
Interventions
- None listed
Full eligibility criteria (from the record)
Inclusion Criteria: * \- Age 2 to 18 years * Chronic gastrointestinal symptoms of more than 4 weeks duration (chronic diarrhea, recurrent abdominal pain, rectal bleeding, unexplained weight loss, or failure to thrive) * Scheduled for upper gastrointestinal endoscopy and/or ileocolonoscopy with mucosal biopsy * Written informed consent from parents or legal guardians Exclusion Criteria: * Age below 2 years * Use of NSAIDs, systemic corticosteroids, or antibiotics within 4 weeks before stool sampling * Documented acute gastrointestinal infection, surgical gastrointestinal bleeding, or intestinal parasitic infestation * Previous gastrointestinal surgery, known malignancy, chronic liver disease, chronic kidney disease, or cystic fibrosis * Refusal of parents or legal guardians to participate * Failure to obtain an adequate stool sample
Locations (0)
No sites listed yet. The official record has contact information.
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.